2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Radiation Therapy, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bone Marrow Failure Syndromes, Hemoglobinopathies, Infectious Diseases, Viral, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

5742 Timing of tocilizumab (Prophylactic versus Early versus Late), cytokine release syndrome (CRS) duration, and unplanned hospital admissions with bispecific antibodies (BsAbs) in relapsed/refractory multiple myeloma (RRMM)

Asayen Viengmany, PharmD, Ashley Chen, PharmD, BCOP2, Miryoung Kim, PharmD, BCOP3, Yuzheng Zhang4, Chad Qianchuan He, PhD5, Kara Cicero Jr, MD, MPH6, Madhav V. Dhodapkar, MD7, Danai Dima, MD8, Laahn Foster, MD9, Mary Kwok, MD10, Andrew Jay Portuguese, MD11, Richa Thakur, MD12, Rahul Banerjee, MD13
1 Fred Hutchinson Cancer Research, Seattle, Washington, United States
2 Fred Hutchinson Cancer Research, Seattle, Washington, United States
3 Fred Hutchinson Cancer Research, Seattle, Washington, United States
4 Fred Hutchinson Cancer Research, Seattle, Washington, United States
5 Fred Hutchinson Cancer Research, Seattle, Washington, United States
6 Fred Hutchinson Cancer Research, Seattle, Washington, United States
7 Fred Hutchinson Cancer Research, Seattle, Washington, United States
8 Fred Hutchinson Cancer Research, Seattle, Washington, United States
9 Fred Hutchinson Cancer Research, Seattle, Washington, United States
10 Fred Hutchinson Cancer Research, Seattle, Washington, United States
11 Fred Hutchinson Cancer Research, Seattle, Washington, United States
12 Fred Hutchinson Cancer Research, Seattle, Washington, United States
13 Fred Hutchinson Cancer Research, Seattle, Washington, United States

Introduction 

CRS remains a challenge with BsAb therapy in RRMM despite step-up dosing. Tocilizumab (toci), an IL-6 receptor antagonist, can treat CRS effectively in this setting and may even be used prophylactically (PPx) before the first dose. For isolated Grade 1 CRS, however, it is not known whether prompt toci administration is clinically necessary to reduce CRS duration, healthcare utilization, or risk of subsequent CRS recurrence.  

Methods 

This single-center retrospective analysis included RRMM patients who initiated commercial BsAb therapy (teclistamab, talquetamab, elranatamab, or linvoseltamab) between October 2022 and April 2026. Notably, for the majority of this timeframe, institutional protocols mandated toci only with ≥ Grade 2 CRS but allowed toci per physician discretion for Grade 1 CRS. Collected data included CRS details, toci treatment information (including exact timing relative to CRS onset), hospitalization lengths of stay or readmission, or modifications to BsAb therapy. CRS duration outcomes were compared utilizing Wilcoxon rank sum test for early versus late toci intervention based on the time interval between CRS onset and toci intervention. Descriptive analysis was conducted for patients who developed grade 1 CRS and did not receive intervention initially.  

Results 

A total of 140 patients were analyzed. Thirty-five patients received PPx toci, of whom 1 (3%) developed CRS; no unplanned hospital admissions occurred in patients who received PPx toci. Among 105 patients who did not receive PPx toci, 52 patients (50%) developed CRS, of whom 27 patients (52%) received ≥1 dose of toci treatment prior to CRS resolution. Toci intervention timing for these 27 patients was divided into early (<12 hours; 14 patients) versus late (≥12 hours; 13 patients). There were 11 subsequent unplanned admissions among these 27 patients. Seven of these patients were subsequently admitted due to CRS, of whom 2 patients received early toci, 1 patient received late toci, and 4 patients received no toci intervention. ICANS was an admitting diagnosis for 3 of these patients as well. 

Early toci recipients experienced a significantly shorter duration of CRS compared to late toci recipients (median 27 hours vs 46 hours, respectively, p <0.001). However, CRS duration from the time of toci administration to resolution was similar between the two groups (median 23 hours vs 22 hours; p = 0.32). CRS recurrence occurred in 5 patients despite toci administration with first CRS event, of whom 2 had received early toci while 3 had received late toci. The median time to resolution of CRS recurrence was similar in early and late toci groups (median 28 hours vs 26 hours; p > 0.99) 

Finally, we separately described 25 patients who developed Grade 1 CRS initially (based on our institutional protocol at the time) but subsequently defervesced without toci or corticosteroids. Of these 25 patients, 11 (44%) subsequently had CRS recurrence; this included 4 patients (16%) who subsequently developed Grade 2 CRS and required tocilizumab intervention later on. Unplanned admissions occurred in 5 (20%) of these 25 patients due to recurrent CRS. 

Conclusion 

Ultimately, PPx toci is the most promising intervention strategy in terms of lowering CRS incidence and rates of unplanned admissions in bispecific agent recipients. For those who received toci only after CRS developed, early toci (<12 hours) initiation was associated with shortened overall CRS duration compared to late toci (>12 hours) initiation. This difference was driven by earlier time to toci administration rather than quicker post-toci CRS resolution. Withholding toci for Grade 1 CRS, even if fevers spontaneously resolve, was associated with high rates of Grade 2 CRS and unplanned admissions, suggesting that toci should be administered within 12 hours of CRS onset even if Grade 1. 

Ashley Chen, PharmD, BCOP: No relevant conflicts of interest to declare.